
CONVERGE: Population medicine has been a spectacular failure, but payers are hindering innovation
Susan Hertzberg, Boston Heart Diagnostics CEO said although genomic sequencing holds a lot of promise beyond cancer treatment, "right here, right now, we have not optimized or used fully what's available."